The Radiochemistry and Instrumentation Support Laboratory (RISL) is one of the core facilities and shared resources of The Ohio State University (OSU) Comprehensive Cancer Center (CCC). The purposes of the RISL are fivefold: (1) to provide custom synthesis of radiochemicals not available commercially to investigators of the OSUCCC, (2) to perform purification of custom preparations of chemically-labile radiochemicals, (3) to aid in the purchase of radiochemicals, advice on the use of radiochemical products and equipment, and provide radiation safety expertise to the CCC, (4) to provide organic chemical support services [synthesis, isolation, structure determination, chemistry expertise] for CCC investigators, and (5) to maintain chemical instrumentation for the isolation and structure determination of carcinogens, drugs, metabolites, and biochemical compounds and general equipment for biochemical/biological research. Robert W. Brueggemeier, Ph.D. is director of the Radiochemistry and Instrumentation Support Laboratory and is involved with projects both as a shared resource person and as a principal investigator within he OSUCCC. Michael V. Darby, Ph.D. serves as the full-time synthetic radiochemist in the Radiochemistry Laboratory. Drs. Brueggemeier and Darby co-direct a graduate research assistant and work closely with cost doctoral research and technicians on the various projects utilizing radiochemistry and chemistry services. Several research and service activities were expanded or introduced since July 1995. These additional services include development of methods of determination of 8-hydroxydeoxyguanosine levels by HPLC- electrochemical detection, expansion of iodination procedures using a variety of reagents, acquisition and installation of new instrumentation and relocation of instruments into laboratory facilities where the instruments are more effectively utilized. The RISL will continue to be an effective radiochemistry and instrumentation support facility for cancer research, diagnosis, or treatment that is encompassed in the OSU Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-27
Application #
6563730
Study Section
Project Start
2001-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
27
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications